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Abstract 
Review on t(4;11)(q21;q23) KMT2A/AFF1 with 
data on clinics and the genes involved. 
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Identity 
t(4;11)(q21;q23) KMT2A/AFF1  G-banding (left) Top two: - Courtesy Diane H. Norback, Eric B. Johnson, and 
Sara Morrison-Delap; bottom three: - Courtesy Adriana Zamecnikova; R- banding (right) - Jean Loup Huret 
(top), - Courtesy Christiane Charrin (middle), - Courtesy Hossein Mossafa (bottom and FISH above). FISH 
below: Hybridization with Vysis LSI MLL break apart rearrangement probe (Abbott Molecular, US) showing 
t(4;11)(q21;q23) KMT2A/AFF1 
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rearrangement of the gene on metaphase and interphase cells as a result of t(4;11)(q21;q23) (split red-green 
signal) - Courtesy Adriana Zamecnikova. 
Clinics and pathology 
Disease 
Translocation t(4;11)(q21;q23) leads to the 
production of the MLL/AF4 (now called KMT2A 
and AFF1 respectively) fusion gene. It accounts for 
approximately 5-10% of newly diagnosed cases of 
Acute Lymphoblastic Leukemia (ALL) mainly in 
children.   Rarely this translocation has been  
reported in biphenotypic ALL, T-ALL, and in acute 
myeloid leukemia usually M4 or M5 subtypes. 
Phenotype/cell stem origin 
The mixed lineage leukemia (MLL) gene located at 
11q23 is a frequently seen target of chromosomal 
translocations in acute leukemias. There are 
currently over 100 different KMT2A (MLL) 
rearrangements identified which can occur in both 
acute myeloid and acute lymphoblastic leukemias, 
with AFF1 (AF4) being the most frequently 
recognized fusion gene. Leukemias expressing 
KMT2A/AFF1, otherwise known as 
t(4;11)(q21;q23) are mainly diagnosed in patients 
with pro-B ALL ( Marchesi et al, 2005).   Cases of 
T-ALL, biphoenotypic ALL and AML (M4 and M5 
types) has also rarely been reported with one study 
showing that in 183 total cases with the 
t(4;11)(q21;q23) only six were AML, one was a T-
ALL, and one was a biphenotypic ALL (Johansson 
Et al, 1998 Leukemia).   Treatment related ALL and 
AML has also been reported in the literature with this 
translocation. 
Epidemiology 
The majority of cases of t(4;11)(q21;q23) positive 
ALL occur in infants less than 6 months old, 
accounting for 50% of ALL in that each group. 
Translocation (4;11)(q21;q23) is detected in 
approximately 10% adults with  newly diagnosed B-
cell ALL, and 30-40% or pro-B ALL subtypes. 
(Moorman et al. Blood 2007).   It can present in older 
ages with one study showing eleven percent 
occurring in patients 50 or older.   Rarely this 
translocation can be seen in M4 or M5 AML, T-ALL 
or treatment related acute leukemia.   In treatment 
related acute leukemia, ALL is more common than 
AML (Johansson et al, 1998, Leukemia).   The 
disease seems to be more common in females than in 
males particularly in those who get the disease under 
six months of age and over 40 years of age. 
Clinics 
Patients typically present with features consistent 
with more aggressive leukemias, including 
hyperleukocytosis (median around 200 X 109/l), 
hepatosplenomegaly and CNS involvement. While 
DIC is uncommon in most forms of ALL, patients 
with this subtype of ALL have a higher incidence of 
DIC at the time of diagnosis. (Pui et al, 1991). 
Pathology 
Blast cells usually display features of early B cell 
leukemia including heavy chain immunglobulin 
gene rearrangement, TDT, HLD-DR, CD34, Cd19, 
CD9 and CD 24 positivity.   Expression of CD 10 
and T cell antigens is rare.  In cases of AML CD 15 
and CD65 are positive and nonspecific esterase and 
myeloperoxidase staining (Carulli et al. 2012). 
Treatment 
Patients with this subtype of ALL have higher risk 
features at diagnosis and overall poor prognosis. 
Common treatment for ALL includes an induction, 
consolidation and maintenance treatment which 
typically lasts about two years.   Drug combinations 
differ based on region and treating physician but 
typically including vincristine, a corticosteroid, 
anthracycline along with L-asparaginase. 
Cyclophosphamide and etoposide are also part of 
some treatment plans along with methotrexate or 
cytarabine.  Intrathecal chemotherapy is given 
during inductoin to prevent CNS involvement. 
Allogenic bone marrow transplantation is indicated 
in certain cases as well.   In patients with B-cell ALL 
rituximab is also used to target CD20.   It is 
important to evaluate for minimal residual disease 
(MRD) by Polymerase chain reaction (PCR) as small 
studies have shown that MRD positivity after 
consolidation is associated with higher incidence of 
relapse and inferior overall survival. However, more 
data from larger studies is needed to establish 
evidence based guidelines for treatment of this 
subset of ALL. (Vey et al, 2012). 
In rare cases of t(4;11) AML, induction 
chemotherapy with antracycline based treatment is 
indicated followed by consolidation and allogenic 
bone marrow transplantation. 
Prognosis 
Rearrangement of the MLL gene confers a poor 
prognosis in both children and adults. Patients with 
t(4;11)(q21;q23) are categorized as having high risk 
disease.    Remission rates of 75 percent have been 
seen but median event free survival has been noted 
of seven months in adults.  In children the complete 
remission rate is around 88% but a median survival 
of 10 months   (Meyer et al, 2006).  In one study of 
infant ALL patients with t(4;11), the five year 
survival rate was only 29 percent (Hilden et al 2006). 
Cytogenetics 
t(4;11)(q21;q23) KMT2A/AFF1  
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i(7q) R- banding - Jean-Loup Huret (left), - 
Courtesy Christiane Charrin (right). 
Additional anomalies 
Additional abnormalities are found in 1/4 of cases at 
diagnosis, clonal evolution to hyperploidy is 
frequent; additional anomalies by decreasing order: 
i(7q) in 10%, +X, + Mar, +6, +8, +19 , +21, +13, 
+10, +14; no difference in outcome was found. 
Variants 
Three way complex t(4;11;Var) exist and showed 
that the crucial event lies on the der(11). 
Genes involved and 
proteins 
Note 
The primary mode of action in which chromosomal 
aberrations can occur to the KMT2A (MLL) gene is 
the reciprocal translocation which results in in-frame 
fusion transcripts with various partner genes. There 
are more than 60 recognized translocation partner 
genes with the most common one being AFF1 
(AF4). The translocation leads to the loss of the 
methyltransferase domain of KMT2A in the 
KMT2A fusion protein. While there are several 
hypothesis regarding the mechanism by which the 
translocation t(4;11)(q21;q23) leads to 
leukemogenesis, the exact mechanism is not known 
(Schnittger et al. 2000).  
 
However, KMT2A/AFF1 binds at specific subsets of 
regulatory elements and direct part of the RUNX1  
gene program, and many others; KMT2A/AFF1 
binds to the BCL2 gene and directly activates it 
through DOT1L recruitment, KMT2A/AFF1 also 
controls the active transcription of MCL1 and 
represses BCL2L11 (BIM) (Konopleva et al. 2017; 
Stunnenberg and Martens, 2017. 
AFF1 (AF4/FMR2 family, member 1) 
Location 
4q21.3 
Note 
AFF1 is the AF4/FMR2 family member 1, also 
known as AF4. 
DNA/RNA 
20 exons, transcript length: 9,390 bps 
Protein 
1,210 amino acids, 131 kDa; AFF1 is bound to 
CDK9 and CCNT1 and is present in all major 
positive transcription elongation factor b (P-TEFb) 
complexes, which stimulates RNA polymerase 
elongation (Lu et al., 2014). 
KMT2A (myeloid/lymphoid or mixed 
lineage leukemia) 
Location 
11q23.3 
Note 
Better known as MLL 
DNA/RNA 
37 exons, spanning about 120 kb; 13-15 mRNA 
Protein 
3969 amino acids, 431 kDa; Transcriptional 
regulatory factor. KMT2A is known to be associated 
with more than 30 proteins, including the core 
components of the SWI/SNF chromatin remodeling 
complex and the transcription complex TFIID. 
KMT2A binds promotors of HOX genes through 
acetylation and methylation of histones. KMT2A is 
a major regulator of hematopoesis and embryonic 
development, through regulation of HOX genes 
expression regulation (HOXA9 in particular). 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
5' KMT2A - 3' AFF1; breakpoints are variable. 
Fusion protein 
Description 
e.g. 2319 amino acids; 240 kDa; N-term AT hook 
and DNA methyltransferase from KMT2A fused to 
AFF1 C-term; the reciprocal ( AFF1/ KMT2A) may 
or may not be expressed; quite similar to the 
KMT2A/ MLLT1  fusion protein found with 
t(11;19)(q23;p13.3) 
Expression / Localisation 
Nuclear localization. 
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